Drug Profile: Humira
Other Names: D2E7, Adalimumab.
Maker: Abbott Laboratories.
Disease Treated: Adult moderate to severe cases of rheumatoid arthritis who have had an inadequate response to disease-modifying anti-rheumatic drugs (DMARDs).
Approval Status: Approved by the US FDA for marketing on December 31, 2002.
Chemical/Biological Nature: HUMIRA is a recombinant all human IgG1 monoclonal antibody specific for human tumor necrosis factor alpha (TNF-α). Components responsible for the antibody’s specificity were discovered by phage display technology (Discovery Medicine, November 2002). The monoclonal antibody is composed of the human antibody heavy and light chain variable regions and human IgG1 constant region. HUMIRA has 1,330 amino acids and ... Read more
